Q2 2018
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ADMA | New | ADMA BIOLOGICS, INC. | $6,464,000 | – | 1,433,304 | – | 99.88% | – |
| MBVXQ | New | MABVAX THERAPEUTICS HOLDINGS, INC. | $8,000 | – | 8,903 | – | 0.12% | – |
Q4 2017
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MBVX | Exit | MABVAX THERAPEUTICS HOLDINGS, INC. | $0 | – | -26,708 | – | -0.02% | – |
| ADMA | Exit | ADMA BIOLOGICS, INC. | $0 | – | -1,433,304 | – | -5.01% | – |
| JUNO | Exit | JUNO THERAPEUTICS, INC. | $0 | – | -1,864,174 | – | -94.97% | – |
Q2 2017
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| JUNO | New | JUNO THERAPEUTICS, INC. | $55,720,000 | – | 1,864,174 | – | 91.26% | – |
| ADMA | New | ADMA BIOLOGICS, INC. | $5,303,000 | – | 1,433,304 | – | 8.68% | – |
| MBVX | New | MABVAX THERAPEUTICS HOLDINGS, INC. | $37,000 | – | 26,708 | – | 0.06% | – |
Q4 2016
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MBVX | Exit | MABVAX THERAPEUTICS HOLDINGS, INC. | $0 | – | -26,708 | – | -0.15% | – |
| ADMA | Exit | ADMA BIOLOGICS, INC. | $0 | – | -1,433,304 | – | -13.73% | – |
| JUNO | Exit | JUNO THERAPEUTICS, INC. | $0 | – | -2,168,601 | – | -86.12% | – |
Q3 2016
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| JUNO | Sell | JUNO THERAPEUTICS, INC. | $65,080,000 | -5.0% | 2,168,601 | -1.7% | 86.12% | -2.0% |
| MBVX | New | MABVAX THERAPEUTICS HOLDINGS, INC. | $113,000 | – | 26,708 | – | 0.15% | – |
| MBVX | Exit | MABVAX THERAPEUTICS HOLDINGS, INC. | $0 | – | -197,641 | – | -0.15% | – |
Q2 2016
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| JUNO | New | JUNO THERAPEUTICS, INC. | $68,516,000 | – | 2,205,926 | – | 87.91% | – |
| ADMA | New | ADMA BIOLOGICS, INC. | $9,302,000 | – | 1,433,304 | – | 11.94% | – |
| MBVX | New | MABVAX THERAPEUTICS HOLDINGS, INC. | $119,000 | – | 197,641 | – | 0.15% | – |